Evermay Wealth Management LLC Has $455,000 Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Evermay Wealth Management LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 789 shares of the medical research company’s stock after buying an additional 36 shares during the period. Evermay Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $455,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Thermo Fisher Scientific by 2.1% during the first quarter. BlackRock Inc. now owns 31,423,285 shares of the medical research company’s stock valued at $18,111,439,000 after acquiring an additional 633,163 shares during the last quarter. Morgan Stanley raised its stake in shares of Thermo Fisher Scientific by 17.7% during the fourth quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after acquiring an additional 1,764,312 shares during the last quarter. FMR LLC raised its stake in shares of Thermo Fisher Scientific by 1.7% during the first quarter. FMR LLC now owns 11,354,044 shares of the medical research company’s stock valued at $6,544,130,000 after acquiring an additional 194,602 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Thermo Fisher Scientific by 1.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,123,657 shares of the medical research company’s stock valued at $5,024,306,000 after acquiring an additional 161,344 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 104,536.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after acquiring an additional 8,347,260 shares during the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Thermo Fisher Scientific Stock Down 2.5 %

Shares of NYSE TMO traded down $13.39 during mid-day trading on Friday, reaching $518.27. 1,834,895 shares of the company’s stock traded hands, compared to its average volume of 1,027,349. The stock has a market cap of $200.03 billion, a P/E ratio of 35.43, a PEG ratio of 2.51 and a beta of 0.77. The business has a 50-day simple moving average of $540.81 and a 200 day simple moving average of $542.61. Thermo Fisher Scientific Inc. has a 1-year low of $475.77 and a 1-year high of $609.85. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.02.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.43 by ($0.28). The business had revenue of $10.69 billion for the quarter, compared to analyst estimates of $10.99 billion. Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.51 earnings per share. On average, analysts expect that Thermo Fisher Scientific Inc. will post 22.37 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 15th will be given a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 9.57%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. Royal Bank of Canada lifted their target price on shares of Thermo Fisher Scientific from $662.00 to $698.00 in a research note on Thursday, July 27th. Credit Suisse Group raised shares of Thermo Fisher Scientific from a “neutral” rating to an “outperform” rating and set a $620.00 target price for the company in a research note on Thursday, July 13th. Raymond James lifted their target price on shares of Thermo Fisher Scientific from $595.00 to $630.00 and gave the stock an “outperform” rating in a research note on Friday, July 28th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $590.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Finally, Citigroup began coverage on shares of Thermo Fisher Scientific in a research note on Wednesday. They set a “buy” rating and a $625.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $631.71.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 3,000 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the completion of the sale, the executive vice president now directly owns 17,556 shares of the company’s stock, valued at $9,792,210.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Gianluca Pettiti sold 3,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total value of $1,673,310.00. Following the transaction, the executive vice president now directly owns 17,556 shares of the company’s stock, valued at approximately $9,792,210.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen Williamson sold 14,100 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $550.00, for a total transaction of $7,755,000.00. Following the completion of the transaction, the chief financial officer now directly owns 27,393 shares in the company, valued at $15,066,150. The disclosure for this sale can be found here. Insiders have sold a total of 28,700 shares of company stock valued at $15,799,270 in the last 90 days. 0.32% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.